API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
LY03010 (paliperidone palmitate) Prolonged Release Suspension for Injection is a central dopamine type 2 (D2) and serotonin type 2 (5HT2A) receptor antagonism which isused to treat schizophrenia.
Lead Product(s): Paliperidone Palmitate
Therapeutic Area: Psychiatry/Psychology Product Name: LY03010
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2023
Details:
Palmeux (paliperidone palmitate) is a second-generation antipsychotic, also known as an atypical antipsychotic (simultaneous serotonin and dopamine antagonist) for the treatment of schizophrenia in adult patients.
Lead Product(s): Paliperidone Palmitate
Therapeutic Area: Psychiatry/Psychology Product Name: Palmeux
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 17, 2023
Details:
LY03010 (paliperidone palmitate) injection is a central dopamine type 2 (D2) and serotonin type 2 (5HT2A) receptor antagonism which isused to treat schizophrenia.
Lead Product(s): Paliperidone Palmitate
Therapeutic Area: Psychiatry/Psychology Product Name: LY03010
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 28, 2022
Details:
LY03010 (paliperidone palmitate) extended-release injectable suspension is a central dopamine type 2 (D2) and serotonin type 2 (5HT2A) receptor antagonism which isused to treat schizophrenia.
Lead Product(s): Paliperidone Palmitate
Therapeutic Area: Psychiatry/Psychology Product Name: LY03010
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 21, 2022
Details:
Byannli (1/3-month paliperidone palmitate) is a central dopamine type 2 (D2) and serotonin type 2 (5HT2A) receptor antagonism which isused to treat schizophrenia.
Lead Product(s): Paliperidone Palmitate
Therapeutic Area: Psychiatry/Psychology Product Name: Byannli
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 01, 2022
Details:
The EC approval is based on the Route 6 Study, a randomised, double-blind, non-inferiority Phase 3 global study designed to demonstrate that BYANNLI® (Paliperidone Palmitate; PP6M) is not less effective than PP3M for the prevention of Schizophrenia.
Lead Product(s): Paliperidone Palmitate
Therapeutic Area: Psychiatry/Psychology Product Name: Byannli
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 23, 2021
Details:
Byannli (6-month paliperidone palmitate) is a central dopamine type 2 (D2) and serotonin type 2 (5HT2A) receptor antagonism which isused to treat schizophrenia.
Lead Product(s): Paliperidone Palmitate
Therapeutic Area: Psychiatry/Psychology Product Name: Byannli
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 17, 2021
Details:
INVEGA HAFYERA (1-month paliperidone palmitate) is a central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism which isused to treat schizophrenia.
Lead Product(s): Paliperidone Palmitate
Therapeutic Area: Psychiatry/Psychology Product Name: Invega Hafyera
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 01, 2021
Details:
LY03010 (paliperidone palmitate) extended-release injectable suspension is a central dopamine type 2 (D2) and serotonin type 2 (5HT2A) receptor antagonism which isused to treat schizophrenia.
Lead Product(s): Paliperidone Palmitate
Therapeutic Area: Psychiatry/Psychology Product Name: LY03010
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 22, 2020
Details:
Byannli (6-month paliperidone palmitate) is a central dopamine type 2 (D2) and serotonin type 2 (5HT2A) receptor antagonism which isused to treat schizophrenia.
Lead Product(s): Paliperidone Palmitate
Therapeutic Area: Psychiatry/Psychology Product Name: Byannli
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 04, 2020
Details:
Invega Hafyera (3-month paliperidone palmitate) is a central dopamine type 2 (D2) and serotonin type 2 (5HT2A) receptor antagonism which isused to treat schizophrenia.
Lead Product(s): Paliperidone Palmitate
Therapeutic Area: Psychiatry/Psychology Product Name: Invega Hafyera
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2020